Financing Technology's Frontier: Decision-Making Models for Investors and Advisors

Front Cover
John Wiley & Sons, Mar 22, 2004 - Business & Economics - 248 pages
An indispensable resource for anyone interested in the future of emerging technology industries
Financing Technology's Frontier draws upon the experiences of today's most successful venture capitalists and entrepreneurs to provide investment professionals expert insight and powerful tools for identifying and capitalizing on the most promising high-tech and biotech opportunities. It also includes proven business models and many fascinating and instructive case studies that help entrepreneurs, CEOs and CFOs learn from the successes and setbacks of other companies in their sectors.
Richard Shanley (New York, NY) is a partner in the Health Services and New Media division at Deloitte Touche Tohmatsu.
 

What people are saying - Write a review

We haven't found any reviews in the usual places.

Selected pages

Contents

CHAPTER 1 Sharing the Excitement of Discovery
1
CHAPTER 2 Growth Models that Encourage Investment
9
CHAPTER 3 Where to Find CapitalPart I Venture Capital
26
CHAPTER 4 Where to Find CapitalPart II Public Markets and Private Placements
53
CHAPTER 5 Creative and Alternative Financing Strategies
77
CHAPTER 6 Strategic Alliances and Corporate Partnerships
116
CHAPTER 7 Mergers and Acquisitions
143
CHAPTER 8 Profiles of Corporate Partnerships
151
CHAPTER 9 Tax Planning Strategies
163
CHAPTER 10 How to Attract and Retain Quality Employees and Management Teams
183
CHAPTER 11 Corporate Governance in a PostEnron World
205
CHAPTER 12 Biotechnology Beyond the US Borders
216
CHAPTER 13 Technologys FutureThe View from the Frontier
228
Afterword
243
Index
245
Copyright

Other editions - View all

Common terms and phrases

About the author (2004)

Richard P. Shanley is a Partner in Deloitte Touche Tohmatsu serving in the northeast region of their healthcare and life sciences industry practice. He has over twenty-seven years of diversified professional services experience, encompassing audits and public stock offerings for biotech, pharmaceutical, and high-tech companies. He has founded and led industry practice groups in both health sciences and new media, and is a recognized authority on financing for emerging growth companies.

Bibliographic information